Committed to bring innovative medications to the Greater China
Close collaboration with local government，research institutes and medical societies to provide medical solution to unmet clinical needs
To rapidly commercialize targeted new drugs and medications under challenging regulatory environment and market access
TransConTM TECHNOLOGY
▼Parent drug is transiently bound to linker-carrier, which inactivates and shields it from clearance
▼Following injection, the linker is designed to auto-hydrolyze at specific rates to predictably release unmodified parent drug
▼Designed to distribute parent drug compound like the endogenous compound; linker-carrier is cleared renally
▼Predictable release of unmodified parent drug supporting dosing frequency from daily to up to six months or more
▼Enables sustained localized or systemic drug exposure
▼Reduces dosing frequency to improve patient adherence and improve overall treatment outcomes
▼Same mode of action as parent drug
▼Same established safety profile as parent drug with potential enhancements or improvements due to application of TransCon technologies
▼Enables comparable alternative to continuous infusions or subcutaneous injections
▼Patent for invention（New composition of matter patents）
▼Exclusive license to develop and commercialize Ascendis Pharma’s endocrinology therapies in Greater China
